3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Head & Neck
1
Genitourinary
1
Conditions
Prostatic Neoplasms
15
Prostatic Neoplasms, Castration-Resistant
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Uveal Melanoma
1
Urothelial Cancer
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Sarcoma
1
Prostatic Diseases
1
Prostate Carcinoma Metastatic to the Bone
1
Prostate Adenocarcinoma
1
Penile Neoplasms
1
Ovarian Diseases
1
Neoplasms
1
Neoplasm Metastasis
1
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
1
Metastatic Castration-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-resistant Prostate Cancer
1
Mesothelioma
1
Melanoma
1
Lung Neoplasms
1
Leukemia, Prolymphocytic, T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
pembrolizumab
3
Trastuzumab
2
Nivolumab
2
tucatinib
1
regorafenib
1
pertuzumab
1
niraparib
1
milademetan
1
dostarlimab
1
cobimetinib
1
brigimadlin
1
atezolizumab
1
alectinib
1
Vemurafenib
1
Tomography, X-Ray Computed
1
Ramucirumab
1
Radiation
1
Positron-Emission Tomography
1
Paclitaxel
1
Magnetic Resonance Imaging
1
HhAntag691
1
Fulvestrant
1
Erlotinib Hydrochloride
1
Clinical Trials, Phase II as Topic
1
Carboplatin
1
Brachytherapy
1
Antibodies
1
AZD9833
1
AZD5305
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
niraparib
×
Genitourinary
×
Clear all
NCT04779151
2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Terminated
51 enrolled